BRPI0916904A2 - polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos - Google Patents

polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos

Info

Publication number
BRPI0916904A2
BRPI0916904A2 BRPI0916904A BRPI0916904A BRPI0916904A2 BR PI0916904 A2 BRPI0916904 A2 BR PI0916904A2 BR PI0916904 A BRPI0916904 A BR PI0916904A BR PI0916904 A BRPI0916904 A BR PI0916904A BR PI0916904 A2 BRPI0916904 A2 BR PI0916904A2
Authority
BR
Brazil
Prior art keywords
patient
ecd
polynucleotide
polypeptides
methods
Prior art date
Application number
BRPI0916904A
Other languages
English (en)
Inventor
Ali Sadra
Deborah H Charych
Shannon Marshall
Original Assignee
Fiveprime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fiveprime Therapeutics Inc filed Critical Fiveprime Therapeutics Inc
Publication of BRPI0916904A2 publication Critical patent/BRPI0916904A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0916904A 2008-08-04 2009-08-04 polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos BRPI0916904A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8612108P 2008-08-04 2008-08-04
PCT/US2009/052704 WO2010017198A2 (en) 2008-08-04 2009-08-04 Fgfr extracellular domain acidic region muteins

Publications (1)

Publication Number Publication Date
BRPI0916904A2 true BRPI0916904A2 (pt) 2016-10-11

Family

ID=41110955

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916904A BRPI0916904A2 (pt) 2008-08-04 2009-08-04 polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos

Country Status (10)

Country Link
US (2) US8338569B2 (pt)
EP (1) EP2318529B1 (pt)
JP (1) JP5787757B2 (pt)
CN (1) CN102171343B (pt)
AU (1) AU2009279806B2 (pt)
BR (1) BRPI0916904A2 (pt)
CA (1) CA2732449A1 (pt)
IL (1) IL210914A (pt)
RU (1) RU2509774C2 (pt)
WO (1) WO2010017198A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
HRP20150512T1 (hr) 2007-09-04 2015-06-19 Compugen Ltd. Polipeptidi i polinukleotidi, te njihova uporaba kao ciljnih molekula za proizvodnju lijekova i bioloških sredstava
EA024751B8 (ru) 2008-06-04 2020-01-31 Амген Инк. Мутанты fgf21 и их применение
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
SMT202400036T1 (it) 2009-05-05 2024-03-13 Amgen Inc Mutanti fgf21 e loro utilizzi
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
WO2011034940A1 (en) * 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
HK1202240A1 (en) 2011-11-14 2015-09-25 戊瑞治疗有限公司 Methods of treating cancer
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
US9617336B2 (en) 2012-02-01 2017-04-11 Compugen Ltd C10RF32 antibodies, and uses thereof for treatment of cancer
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201504815QA (en) 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
EP2970422B1 (en) 2013-03-15 2018-04-18 F.Hoffmann-La Roche Ag Il-22 polypeptides and il-22 fc fusion proteins and methods of use
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
TN2016000035A1 (en) 2013-07-31 2017-07-05 Amgen Inc Growth differentiation factor 15 (gdf-15) constructs
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
SI3242888T1 (sl) * 2015-01-07 2021-07-30 Pfizer Inc. Topne vabe FGFR3 za zdravljenje motenj rasti skeleta
WO2016191765A1 (en) * 2015-05-28 2016-12-01 Remegen, Ltd. Fgfr-fc fusion proteins and the use thereof
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
RU2751483C2 (ru) 2016-07-07 2021-07-14 Пфайзер Инк. Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3444275A1 (en) * 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
ES3014001T3 (en) 2018-12-07 2025-04-16 Remegen Co Ltd Bifunctional angiogenesis inhibitor and use thereof
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486462A (en) 1984-11-23 1996-01-23 The Regents Of The University Of California Differentiative expression modules
GB9001466D0 (en) 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
HU215581B (hu) 1989-07-06 1999-01-28 Regents Of The University Of California Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
US5750371A (en) 1990-04-27 1998-05-12 Takeda Chemical Industries Ltd Water-soluble mutein of FGF receptor, DNA and production thereof
EP1403285A1 (en) 1990-07-06 2004-03-31 Gencell S.A. Fibroblast growth factor receptors
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
IL100219A0 (en) * 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
DE19802377A1 (de) * 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
EP3342411B1 (en) * 2001-02-19 2019-08-21 Novartis Pharma AG Rapamycin derivative for treating pancreas cancer
US20050187150A1 (en) 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
ES2285188T3 (es) 2002-07-15 2007-11-16 Immunex Corporation Metodo y medios para controlar sialilacion de proteinas producidas por celulas de mamifero.
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
EP1697420A2 (en) 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
CA2565974A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
CA2589895A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
WO2007059574A1 (en) 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
CA2637988A1 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
US7794825B2 (en) * 2006-04-25 2010-09-14 Jeffrey M Kudrick Prefabricated lightweight concrete structure including columns
EP2018442A2 (en) 2006-05-12 2009-01-28 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
JP2010525301A (ja) 2007-03-23 2010-07-22 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 子宮内膜癌および前癌の診断、分類および治療の方法
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
CN101139387B (zh) * 2007-07-20 2011-04-06 暨南大学 一种重组可溶性人fgfr2胞外段及其生产方法与应用
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
MX2012000362A (es) 2009-07-10 2012-11-12 Mckechnie Vehicle Components Usa Inc Uso de revestimiento de material protector que mejora la adhesion de revestimientos de rueda.
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
KR20140012137A (ko) 2011-03-17 2014-01-29 노파르티스 아게 Hr 양성 대상체에서의 유방암용 바이오마커로서의 fgfr 및 이의 리간드
EP2723391B1 (en) 2011-06-24 2018-06-13 University of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
HK1202240A1 (en) 2011-11-14 2015-09-25 戊瑞治疗有限公司 Methods of treating cancer

Also Published As

Publication number Publication date
AU2009279806B2 (en) 2015-04-30
RU2509774C2 (ru) 2014-03-20
WO2010017198A3 (en) 2010-04-29
CA2732449A1 (en) 2010-02-11
IL210914A (en) 2016-09-29
IL210914A0 (en) 2011-04-28
AU2009279806A1 (en) 2010-02-11
US9175065B2 (en) 2015-11-03
EP2318529B1 (en) 2017-10-18
JP2011529705A (ja) 2011-12-15
US8338569B2 (en) 2012-12-25
CN102171343B (zh) 2017-07-14
EP2318529A2 (en) 2011-05-11
JP5787757B2 (ja) 2015-09-30
US20130004492A1 (en) 2013-01-03
US20100087627A1 (en) 2010-04-08
WO2010017198A2 (en) 2010-02-11
RU2011103972A (ru) 2012-09-10
CN102171343A (zh) 2011-08-31

Similar Documents

Publication Publication Date Title
BRPI0916904A2 (pt) polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
BR112015002765A2 (pt) proteína de fusão, polinucleotídeo, vetor, célula hospedeira, métodos para produzir a proteína de fusão, de tratamento de uma doença em um indivíduo e para ativação seletiva in vitro ou in vivo de células reguladoras, composição farmacêutica, uso da proteína de fusão e invenção.
BRPI1013559A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos
BR112013011968A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BR112014024209A2 (pt) composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar
SMT201600313B (it) Derivati di solfonammide come agenti che inducono apoptosi selettivi per bcl-2 per il trattamento del cancro e dei disturbi immunitari
UA113856C2 (xx) Злитий білок для лікування порушень метаболізму
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BR112012008074A2 (pt) derivados de piridina e pirazina como moduladores de proteína quinase
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
CL2014002549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BR112012029611A2 (pt) proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
BRPI1010109A2 (pt) proteína de ligação ao antígeno tetravalente e biespecífica, método para a preparação de uma proteína de ligação ao antígeno tetravalente e biespecífica, célula hospedeira, composição farmacêutica, uso da proteína de ligação ao antígeno tetravalente biespecífica e método para o tratamento de um paciente que necessita de terapia
BR112015004734A2 (pt) proteínas de fusão para tratar uma síndrome metabólica
BR112014022708A8 (pt) uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BRPI0814465A2 (pt) Proteína de fusão, proteína multimérica, métodos para produzir uma proteína de fusão, e para estimular a produção de célula sanguínea branca em um mamífero, linhagem de célula, composição farmacêutica, e molécula de dna recombinante
CY2016053I1 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
BR112014019750A2 (pt) composto, composlção farmacêutlca, método para aumentar a lnclusão de éxon 7 de smn2 em mrna, método para aumentar a quantidade de proteína smn e método para tratar sma em um indivíduo humano em necessidade
PL3517539T3 (pl) Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
FR2928924B1 (fr) Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
BRPI0905752A2 (pt) "muteína de lipocalina da lágrima humana (htlc), molécula de ácido nucléico, célula hospedeira, composição farmacêutica, método para a produção de uma muteína de lipocalina da lágrima humana, método de tratamento de uma doença ou distúrbio e uso de uma mateína de lipocalina da lágrima humana"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B350 Update of information on the portal [chapter 15.35 patent gazette]